Our
Clients
Market Overview
The global Gastric Cancer Therapy market was valued at USD 7.67 billion in 2022 and expected to grow at a CAGR of 8.8% during the forecast period. Gastric cancer therapy refers to the treatment of cancer that originates in the stomach. Gastric cancer is a type of cancer that starts in the cells lining the stomach and is also known as stomach cancer. The therapy can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The type of treatment used depends on the stage of the cancer, the location of the cancer in the stomach, and the overall health of the patient. The aim of gastric cancer therapy is to cure the cancer, control its spread, and improve the patient's quality of life. The global market for gastric cancer therapy is expected to grow significantly in the coming years due to the increasing incidence of gastric cancer, particularly in the Asia Pacific region. The market is driven by the rising adoption of combination therapies, targeted therapies, and immunotherapies. The market is also being influenced by the introduction of novel therapies and the development of personalized medicine approaches.
Increasing incidence of gastric cancer: The incidence of gastric cancer has been increasing globally, particularly in Asia and Latin America. This has resulted in a growing demand for effective therapies to treat the disease.
Technological advancements in cancer therapy: Advances in cancer therapies, such as targeted therapies and immunotherapies, have improved treatment outcomes and increased the survival rates of patients with gastric cancer.
Growing awareness of early detection and screening: Early detection and screening of gastric cancer have been shown to improve treatment outcomes and increase the chances of survival. This has led to an increased awareness of the importance of screening and early detection among patients and healthcare providers.
Favorable reimbursement policies: Favorable reimbursement policies for gastric cancer therapies have encouraged patients to seek treatment and have increased the availability of effective therapies.
Increasing healthcare expenditure: Increasing healthcare expenditure in both developed and developing countries has provided greater access to advanced cancer therapies, including those for gastric cancer.
High cost of cancer therapy: The cost of cancer therapy, particularly advanced therapies such as immunotherapies, can be prohibitively expensive, limiting their accessibility to many patients.
Adverse side effects of therapy: Many cancer therapies, including chemotherapy and radiation therapy, can have adverse side effects that can be difficult for patients to tolerate.
Lack of effective therapies for advanced or metastatic gastric cancer: While there have been significant advances in the treatment of early-stage gastric cancer, effective therapies for advanced or metastatic disease remain limited.
Complex regulatory and reimbursement landscape: The complex regulatory and reimbursement landscape for cancer therapies can make it challenging for patients and healthcare providers to access and afford effective therapies.
Impact of COVID-19: The COVID-19 pandemic has had a significant impact on the Gastric Cancer Therapy Market, disrupting supply chains and clinical trials and leading to delays in diagnosis and treatment.
The major players in the market are focused on developing innovative therapies for the treatment of gastric cancer. These companies are investing heavily in research and development to bring new therapies to the market. The market is also being driven by the increasing demand for minimally invasive surgeries, which offer patients quicker recovery times and less pain.
The COVID-19 pandemic has had a significant impact on the market, with delays in diagnosis and treatment leading to a decrease in demand for cancer therapies. However, with the easing of restrictions and the resumption of elective procedures, the market is expected to recover.
North America and Europe are the largest markets for gastric cancer therapy, but the Asia Pacific region is expected to show the fastest growth due to the high incidence of gastric cancer in countries such as Japan, China, and South Korea.
Report Scope
Report Attributes | Description |
Market Size in 2022 | USD 7.67 Billion |
Market Forecast in 2031 | USD 10.85 Billion |
CAGR % 2023-2031 | 8.8% |
Base Year | 2022 |
Historic Data | 2019-2021 |
Forecast Period | 2023-2031 |
Report USP | Production, Consumption, company share, company heatmap, company production capacity, growth factors and more |
Segments Covered | By Therapy Type, By End User |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Bristol-Myers Squibb, Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Sanofi, Astrazeneca, and Amgen. |
Impact of COVID
The COVID-19 pandemic has had a significant impact on the Gastric Cancer Therapy Market. Many hospitals and clinics have been overwhelmed with COVID-19 patients, which has resulted in a reduction in the number of patients seeking diagnosis and treatment for gastric cancer. Additionally, the disruption of global supply chains has led to shortages of certain cancer drugs and delayed clinical trials. However, the increasing adoption of telemedicine and virtual consultations has helped to mitigate some of these challenges by allowing patients to continue receiving care remotely. The market is expected to gradually recover as the COVID-19 situation improves and healthcare systems are better equipped to handle both COVID-19 and other diseases.
Therapy Type Insights
Chemotherapy: Chemotherapy is a common treatment option for gastric cancer and includes drugs such as fluorouracil, cisplatin, oxaliplatin, and capecitabine. Chemotherapy holds the largest share in the gastric cancer therapy market.
Targeted Therapy: Targeted therapy is a type of cancer treatment that targets specific genes or proteins that are involved in the growth and survival of cancer cells. Targeted therapies for gastric cancer include trastuzumab, ramucirumab, and apatinib.
Immunotherapy: Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer. Immunotherapy drugs used in gastric cancer include pembrolizumab and nivolumab.
Radiation Therapy: Radiation therapy uses high-energy radiation to kill cancer cells. Radiation therapy is often used in combination with other treatments for gastric cancer.
Surgery: Surgery is a common treatment option for early-stage gastric cancer. Surgery involves removing the cancerous part of the stomach or the entire stomach.
End-user Insights
North America holds a significant share of the market due to the high prevalence of gastric cancer and the availability of advanced medical facilities.
Asia Pacific is expected to show the highest growth rate during the forecast period due to the increasing prevalence of gastric cancer, a large patient pool, and growing healthcare expenditure in countries such as China, Japan, and India.
Europe is also a significant market for gastric cancer therapy due to the increasing aging population and growing awareness of gastric cancer.
Latin America and the Middle East & Africa are expected to have a moderate growth rate due to the limited availability of advanced medical facilities and the low awareness regarding gastric cancer therapy.
Regional Insights
Ambulatory surgery centers provide same-day surgical care and offer convenience to patients with less complex surgical needs. These centers are equipped with advanced technologies and can perform procedures in a more cost-effective manner than hospitals. As a result, many patients prefer ambulatory surgery centers for their treatment, including gastric cancer therapy.
Hospitals are the primary healthcare providers for patients with complex and critical medical conditions, including gastric cancer. They have a range of specialists and resources available to provide comprehensive care, including surgery, chemotherapy, and radiation therapy.
Specialty clinics are another important end user for gastric cancer therapy. These clinics are typically smaller and focused on a specific area of medicine, such as cancer treatment. They may offer specialized treatments and procedures that are not available in larger healthcare facilities.
The choice of end user for gastric cancer therapy may depend on various factors such as the severity of the condition, patient preference, and availability of resources. Overall, a combination of these end users may be involved in the treatment of gastric cancer patients to ensure optimal outcomes.
Competitive Analysis
Some of the major companies operating within the market are Bristol-Myers Squibb, Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Sanofi, Astrazeneca, and Amgen. These players are focusing on product innovation, expansion, and partnerships to strengthen their market position and meet the growing demand for Gastric Cancer Therapy globally.
By Therapy Type
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Surgery
By End User
Ambulatory Surgery Centers
Hospitals and Specialty Clinics
Others
Why to buy this Report?
The report provides quantitative and qualitative aspect for the market in terms of value and volume, along with supporting market trends, challenges, restraints.
The report provides an in depth analysis from both production and consumption point of view at the regional and country level. Key Factors considered within the report scope are Production capacity by countries/regions, average price, consumption ratio, revenue earned and gross margin.
The report provides competitive analysis of around 30-50 companies operated in the market, these companies are bifurcated into niche players, the leaders and major contenders. The companies are analyzed in terms of following factors such as:
Business Model
Production Capacity, Revenue, Sales, Gross Margin
Key Business Strategy
SWOT Analysis
In terms of competitive landscape, the report provides distinctive factors that would help the end user in taking a key decision within the business:
Company Share Analysis from 2018-2022
Company Analysis by Revenue and Sales
Company Production Capacity, Gross Margin
Company Share Analysis by Application/End Use
Company Share Analysis by Product/Specification
Frequently Asked Questions
What is the market size and growth projections?
What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?
What are the top performing segments, and countries / regions of each of the markets?
What is the market size and growth rate across key countries / regions?
How big is the global & regional market in terms of revenue and volume?
How far market will grow in forecast period in terms of revenue and volume?
What factors will influence demand and supply trends across each markets during the forecast period?
What are the technology trends shaping various markets?
Which country / region has more opportunities?
What is the COVID-19 impact on the market and how long will it take to recover?
Who are the key competitors of market Players?
What are the market share (%) of Key Players?
What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?
